BCL-2 is frequently overexpressed in a number of B-cell malignancies, including CLL, due to the increased transcription or loss of miRNAs that act as its negative regulators [15,16]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.